Asset profile

VIASKIN Peanut Patch · DBV Technologies (DBVT)

Indication: peanut allergy in children aged 4-7 years
Also known as: VIASKIN Peanut Patch, VIASKIN® Peanut Patch, VIASKIN Peanut, VIASKIN Peanut 250 µg, patch VIASKIN Peanut, epicutaneous peanut immunotherapy

Company

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its pr…

Start live analysis of DBVT Run 8-agent AI analysis Stock overview

On the calendar

Jun 2026

Jun 12, 2026

96 days ago

DBVTDBV Technologies

DBV Technologies presents VITESSE subgroup data and THRIVE protocol at EAACI 2026

Conference presentationOutcome not recordedCompany press release

Nov 2026

~ Nov 2026

DBVTDBV Technologies

VIASKIN Peanut Patch: Phase 3 trial NCT07003919 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

Material

Jun 29, 2026

08:28 PM

DBVTDBV Technologies

DBV Technologies delays VIASKIN Peanut Patch BLA to Q3 2026

Application submittedSEC 8-K Open record

Material

Jun 29, 2026

08:00 PM

DBVTDBV Technologies

DBV Technologies delays VIASKIN Peanut Patch BLA to Q3 2026

Application submittedCompany press release Open record

Notable

Jun 29, 2026

08:00 PM

DBVTDBV Technologies

DBV Technologies delays VIASKIN Peanut BLA filing to Q3 2026

Application submittedCompany press release

Notable

Jun 8, 2026

08:35 PM

DBVTDBV Technologies

DBV Technologies presents VITESSE subgroup data and THRIVE protocol at EAACI 2026

Conference presentationCompany press release

Material

Apr 30, 2026

09:30 PM

DBVTDBV Technologies

DBV Technologies plans VIASKIN Peanut Patch BLA filing H1 2026

Application submittedSEC 8-K Open record

Material

Mar 26, 2026

09:25 PM

DBVTDBV Technologies

DBV Technologies: BLA submission for VIASKIN Peanut Patch (4-7 yrs) planned H1 2026

Application submittedSEC 8-K Open record

Decision-grade

Mar 2, 2026

12:54 PM

DBVTDBV Technologies

DBV Technologies: VITESSE Phase 3 VIASKIN Peanut Patch meets primary endpoint

Topline resultsSEC 8-K Open record1 update

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 15, 2026

Primary endpoint metFavourable

DBV Technologies: VITESSE Phase 3 VIASKIN Peanut Patch meets primary endpoint

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

213 of 369 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

DBVTDBV TechnologiesOwner

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT05741476	Phase 3	Active, not recruiting	Nov 6, 2025	600	50 of 87 sites in the United States
NCT07003919	Phase 3	Active, not recruiting	Nov 1, 2026	480	56 of 91 sites in the United States
NCT03211247	Phase 3	Completed	Aug 20, 2019	414	27 of 51 sites in the United States
NCT02636699	Phase 3	Completed	Aug 18, 2017	500	17 of 31 sites in the United States
NCT03013517	Phase 3	Unknown	Nov 23, 2019	300	17 of 31 sites in the United States
NCT01955109	Phase 2	Completed	Sep 1, 2016	171	10 of 22 sites in the United States
NCT01675882	Phase 2	Completed	Jul 1, 2014	221	10 of 24 sites in the United States
NCT02916446	Phase 3	Completed	Sep 22, 2017	393	26 of 32 sites in the United States